Evidence map›Paper›PMID 22639787›Full record

ArticleJournal of proteome research2012

Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies.

Amol Prakash, Taha Rezai, Bryan Krastins, David Sarracino, Michael Athanas, Paul Russo, Hui Zhang, Yuan Tian, Yan Li, Vathany Kulasingam and 12 more

Registry-linked trialOpen access · greenAbstract readMulticenter Study
In one paragraph

Article in Journal of proteome research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05338060 (A Systems Approach to Immunotherapy Biomarker Identification Within the Postoperative Wound-Healing Microenvironment in Patients With Gastroesophageal Cancer), which is not on this map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05338060 completednot on this mapstarted 2022, after this paper: background citation

A Systems Approach to Immunotherapy Biomarker Identification Within the Postoperative Wound-Healing Microenvironment in Patients With Gastroesophageal Cancer

TypeobservationalSponsorInova Health Care ServicesRan2022 to 2025Enrolled10ConditionsGastroEsophageal CancerArmsprospective collection of surgical exudates (SEs)
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 67 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Clinical potential of mass spectrometry-based proteogenomics.Nature reviews. Clinical oncology · 2019
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 3 countries.

Amol PrakashThermo Fisher Scientific, BRIMS (Biomarker Research in Mass Spectrometry), Cambridge, Massachusetts 02139, United States. amol.prakash@thermofisher.com
Taha Rezai
Bryan Krastins
David Sarracino
Michael Athanas
Paul Russo
Hui Zhang
Yuan Tian
Yan Li
Vathany Kulasingam
Andrei Drabovich
Christopher R Smith
Ihor Batruch
Paul E Oran
Claudia Fredolini
Alessandra Luchini
Lance Liotta
Emanuel Petricoin
Eleftherios P Diamandis
Daniel W Chan
Randall Nelson
Mary F Lopez
Thermo Fisher Scientific (United States) · USGeorge Mason University · USJohns Hopkins University · USMount Sinai Hospital · CAArizona State University · USUniversity of Toronto · CAInstitute of Biophysics · CN

Funding

Team Approach to Translate Novel Biomarkers for DiabetesR24DK090958 · NIDDK · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI NELSON, RANDALL W, PEARSON, JAMES DAVID · 2011 to 2014
$4.5M
Population-Based Proteomic Investigation of Type 2 Diabetes MellitusR01DK082542 · NIDDK · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI NELSON, RANDALL W · 2010 to 2014
$3.0M
Nanotrap technology for one step preservation and amplification of cancer biomarkR33CA173359 · NCI · GEORGE MASON UNIVERSITY · PI LIOTTA, LANCE ALLEN · 2012 to 2014
$1.1M
NCI NIH HHS R33 CA173359NIDDK NIH HHS R01 DK082542NIDDK NIH HHS R24 DK090958
6 · The paper itself

Abstract

Over the past few years, mass spectrometry has emerged as a technology to complement and potentially replace standard immunoassays in routine clinical core laboratories. Application of mass spectrometry to protein and peptide measurement can provide advantages including high sensitivity, the ability to multiplex analytes, and high specificity at the amino acid sequence level. In our previous study, we demonstrated excellent reproducibility of mass spectrometry-selective reaction monitoring (MS-SRM) assays when applying standardized standard operating procedures (SOPs) to measure synthetic peptides in a complex sample, as lack of reproducibility has been a frequent criticism leveled at the use of mass spectrometers in the clinical laboratory compared to immunoassays. Furthermore, an important caveat of SRM-based assays for proteins is that many low-abundance analytes require some type of enrichment before detection with MS. This adds a level of complexity to the procedure and the potential for irreproducibility increases, especially across different laboratories with different operators. The purpose of this study was to test the interlaboratory reproducibility of SRM assays with various upfront enrichment strategies and different types of clinical samples (representing real-world body fluids commonly encountered in routine clinical laboratories). Three different, previously published enrichment strategies for low-abundance analytes and a no-enrichment strategy for high-abundance analytes were tested across four different laboratories using different liquid chromatography-SRM (LC-SRM) platforms and previously developed SOPs. The results demonstrated that these assays were indeed reproducible with coefficients of variation of less than 30% for the measurement of important clinical proteins across all four laboratories in real world samples.

Indexed as

Amino Acid SequenceBlood Chemical AnalysisChromatography, Reverse-PhaseFemaleHuman Growth HormoneHumansLaboratoriesLimit of DetectionMaleMass SpectrometryMolecular Sequence DataPeptide FragmentsProstate-Specific AntigenProstatic NeoplasmsReference StandardsReproducibility of ResultsHuman Growth HormonePeptide FragmentsProstate-Specific AntigenSeminal Plasma Proteins

Identifiers

PMID22639787
PMCPMC3761372
OpenAlexW2128564638

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.